Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Synthesis and characterization of a PDMS-PMOXA based polymersomes sensitive to MMP-9 for application in breast cancer
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4486048
Author(s) Porta, Fabiola; Ehrsam, Daniel; Lengerke, Claudia; Meyer Zu Schwabedissen, Henriette E.
Author(s) at UniBasel Meyer zu Schwabedissen, Henriette
Porta, Fabiola
Ehrsam, Daniel
Year 2018
Title Synthesis and characterization of a PDMS-PMOXA based polymersomes sensitive to MMP-9 for application in breast cancer
Journal Molecular pharmaceutics
Volume 15
Number 11
Pages / Article-Number 4884-4897
Mesh terms Animals; Antineoplastic Agents, Phytogenic, pharmacokinetics; Breast Neoplasms, pathology; Drug Carriers, chemical synthesis; Drug Liberation; Embryo, Nonmammalian; Female; Humans; MCF-7 Cells; Matrix Metalloproteinase 9, metabolism; Nanoparticles, chemistry; Oxazoles, chemical synthesis; Paclitaxel, pharmacokinetics; Polymers, chemical synthesis; Treatment Outcome; Xenograft Model Antitumor Assays; Zebrafish
Abstract Cytotoxic compounds used to treat cancer are often associated with adverse events. The development of formulations activated by tumor-specific triggers would allow a reduction of systemic exposure while maintaining therapeutic concentrations in the tumor. One enzyme with proteolytic activity reported to be involved in tumor progression and assumed to be enhanced in the tumor environment is the matrixmetalloproteinase 9 (MMP-9). In our study, we aimed to develop surface modified PDMS-PMOXA polymersomes able to release their cytotoxic payload upon digestion by MMP-9. To test the applicability of such a system in breast cancer, this tumor entity was assessed for MMP-9 expression, supporting breast cancer as a potential target. The surface-modified polymersomes were synthesized and formulated resulting in paclitaxel loaded particles of about 320 ± 153.15 nm in size with a surface potential of 0.04 ± 0.007 mV. After verifying expression and activity of MMP-9 in MCF7 cells, this cell line was used for further analysis. Treatment of MCF7 cells with the polymersomes significantly reduced cell viability, this effect was abolished after addition of MMP-inhibitors, suggesting proteolytic activation. In zebrafish embryos, the polymersomes were observed in the circulation with some enrichment in liver and agglomerates in the caudal veins. Importantly, in zebrafish embryos xenografted with mKate2-expressing MCF7 cells the amount of tumor cells, quantified by detecting the copies of the heterologously expressed fluorescent protein, significantly decreased after treatment with PDMS-PMOXA-SRL paclitaxel polymersomes. Taken together our data suggest that polymersomes modified with an MMP-9 labile peptide and loaded with paclitaxel can be formulated, and that these particles exert pharmacological activity upon enzymatic digestion.
Publisher AMER CHEMICAL SOC
ISSN/ISBN 1543-8392
edoc-URL https://edoc.unibas.ch/67827/
Full Text on edoc No
Digital Object Identifier DOI 10.1021/acs.molpharmaceut.8b00521
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/30274515
ISI-Number WOS:000449577000010
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.328 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
17/06/2024